IMVT

Immunovant (IMVT)

About Immunovant (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

Details

Daily high

$40.33

Daily low

$39.42

Price at open

$39.86

52 Week High

$41.23

52 Week Low

$14.32

Market cap

8.2B

Dividend yield

0.00%

Volume

92,763

Avg. volume

922,481

P/E ratio

-14.35

Immunovant News